• Normalised EBIT up 41.4% with Pro-forma EBIT of $903.4 million
• 20+ year growth profile continues as Sigma reaches 588 CW retail network stores across Australia
• Achieved like-for-like sales growth of 11.3% across the Australian CW retail network

Sigma Healthcare Limited (Sigma) today announced its first financial results since the successful merger with the Chemist Warehouse Group (CWG) for the full year ended 30 June 2025 (FY25), which illustrate the strong growth opportunities of the newly expanded company. Highlights include a 41.4% increase in normalised EBIT with Pro-forma EBIT of $903.4 million, a 20+ year growth profile as Sigma reaches 588 CW retail network stores across Australia, and achieved like-for-like sales growth of 11.3% across the Australian CW retail network. The merger with Chemist Warehouse has delivered a stronger, more integrated healthcare business, with greater scale, capability, and market reach. The FY25 results demonstrate the group's momentum and potential for ongoing growth. Sigma is committed to delivering excellence for its customers, partners and suppliers while strengthening its operations and driving ongoing efficiencies. The company has made good progress executing the integration plan and today announces an upgrade to the merger synergy target from $60 million per annum to $100 million per annum to be achieved within four years. The performance of the Chemist Warehouse retail network was a standout, with total retail network sales to customers for the 12-months up 14% to $10.3 billion. Sigma continues to expand its portfolio of own and exclusive brand products, headlined by the launch of 269 products in the Wagner generics range in November 2024. The company's supply chain reliability and efficiencies are keys to its success, with the combined distribution centre network successfully absorbing a 29% volume increase during the period. Sigma remains focused on optimizing the network to improve service delivery, reduce cost and open new business opportunities.

Sigma anticipates rolling out Chemist Warehouse stores at a consistent cadence to its historical run rate in Australia and internationally, and expects to continue to launch new own and exclusive label products to drive margin improvement. Integration activities are well underway with the bulk of the synergy benefits anticipated in FY27 and beyond.

Sigma is now a stronger more integrated healthcare business - one with scale, capability, market reach and growth pathways. The company has just started the journey to fully realise the benefits of the merger, and FY26 has started strongly with double digit like-for-like retail network sales growth YTD. Sigma is well placed to deliver ongoing growth and sustainable returns to shareholders.